SEP 18, 2019 3:36 PM PDT

How Does Ketamine Treat Depression?

WRITTEN BY: Annie Lennon

In recent years, ketamine has received growing interest for its neuroprotective effects. Known to alleviate symptoms of depression in just hours whereas conventional antidepressants take weeks, studies have also shown its efficacy in helping patients with depression previously deemed untreatable. But how come? How does ketamine work? 

As it turns out, despite having measured its positive effects, researchers are still uncertain how ketamine works. Several theories on how it works exists however. Although purporting different processes, it is nevertheless likely that these processes work together to produce ketamine’s effects, among processes that are as yet unstudied. 

A prominent theory on how ketamine may work is by targeting the brain’s NMDA (N-methyl-D-aspartate) receptors. Binding to these receptors, ketamine seems to increase the amount of glutamate, a neurotransmitter that plays a large role in learning and memory, found in the spaces between neurons. This influx of glutamate the activates α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor (AMPA) receptors. By working with both NMDA and AMPA receptors in this way, ketamine seems to lead to the release of other molecules that enable neurons to communicate along new pathways. A process known as synaptogenesis, it then likely relieves depressive symptoms by positively affecting mood, thought patterns and general cognition (Meisner: 2019). 

Building upon this theory, Alexander Papp, MD, psychiatrist at UC San Diego Health, explained how this process leads to ketamine’s faster treatment times than traditional antidepressants: “The speediness of ketamine in producing an antidepressant effect occurs because this drug bypasses the traditional serotonin route and goes directly to activating glutamate. This is very different from traditional antidepressants, which first increase the activity of serotonin in multiple different areas of the brain, and then ultimately affect glutamate. This process usually takes two to four weeks to take effect, while ketamine yields an almost immediate effect (Johnston: 2017).”

Alternative reasons for ketamine’s effects exist too. For example, researchers at the University of Illinois at Chicago College of Medicine have proposed a theory revolving around G proteins. A family of proteins that function as molecular switches, they pass messages from the cell’s exterior to its interior and are located in areas of the cell membrane known as “lipid rafts” alongside other cellular machinery required for signaling between cells.

Looking into these proteins, the researchers found that those with depression had high quantities of G proteins in their lipid rafts, which were then subsequently turned off. This is likely to have led to reduced neuronal signaling, and perhaps some depressive symptoms. However, after administering ketamine to people with high numbers of G proteins in their lipid rafts, they found that these G proteins left the lipid rafts within just 15 minutes of receipt, alongside depressive symptoms (Wray: 2018). 

According to Professor Mark Rasenick, a leader of the study, “With ketamine, the G proteins are very slow to move back into the lipid rafts, which would explain the drug's long-term effects on depressive symptoms (Newman: 2018).”

To conclude, although research has shown that ketamine is likely effective in treating symptoms of depression and theories exist explaining how this happens, as of yet, there is little consensus on exactly how the drug works. To this end, further research is needed, including trials monitoring usage of the drug in clinical settings in both the short and long term, as well as into the molecular structures within the brain itself. 


 

Sources 

 

Meisner, Robert C.: Harvard Health Publishing

Johnston, Gabrielle: UC San Diego Health 

Wray, Nathan H. et al: Molecular Psychiatry 

Newman, Tim: Medical News Today

About the Author
  • Annie graduated from University College London and began traveling the world. She is currently a writer with keen interests in genetics, psychology and neuroscience; her current focus on the interplay between these fields to understand how to create meaningful interactions and environments.
You May Also Like
JAN 16, 2020
Drug Discovery & Development
JAN 16, 2020
Fatty Acid Supplement Repairs Brain After Stroke in Mice
Researchers have found that supplements containing short chain fatty acids (SCFAs) may be able to help the brain recover from having a stroke. This comes a...
FEB 13, 2020
Cell & Molecular Biology
FEB 13, 2020
Study of Early-Onset Parkinson's Reveals Potential Therapeutic
Around 500,000 Americans are diagnosed with Parkinson's disease every year, and the rate of the disease is rising....
MAR 08, 2020
Microbiology
MAR 08, 2020
A Supercomputer Aids in the Hunt for COVID-19 Therapeutics
It is seeming more likely that COVID-19, caused by the coronavirus SARS-CoV-2, will impact many people....
MAR 06, 2020
Drug Discovery & Development
MAR 06, 2020
Scorpion-derived Proteins Deliver Arthritis Treatment
New research published in the journal Science Translational Medicine shows that that a scorpion-derived proteins could soon provide relief for arthritis. &...
MAR 08, 2020
Drug Discovery & Development
MAR 08, 2020
DNA Origami Helps With Cancer Therapeutics
A study published in the Proceedings of the National Academy of Sciences, describes how researchers designed molecules known as "peptoid-coated DNA or...
MAR 12, 2020
Drug Discovery & Development
MAR 12, 2020
Recent Data Accelerates Coronavirus SARS-CoV2 Drug Discovery
Coronavirus (SARS-CoV-2) is a currently a human health crisis. It is not only highly infectious but results severe pneumonia (COVID-19) in some cases. Now,...
Loading Comments...